Form 4: Cytokinetics Director Nancy Wysenski Receives Equity Grant

Director Nancy Wysenski acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Summary

• Director Nancy Wysenski was granted 2,851 shares of common stock at a price of $0.
• Director Nancy Wysenski was granted 4,301 non-qualified stock options with an exercise price of $77.15.
• The options vest starting June 27, 2026, and expire on May 26, 2036.
• Following these transactions, the director holds 33,917 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a standard director equity compensation filing.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to align director incentives with long-term shareholder value in the biotechnology sector.

Comparison to Industry Standards

• The grant of restricted stock and options is consistent with standard compensation packages for independent directors in mid-cap biopharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation practices.

Next Steps

• Vesting of stock options beginning June 27, 2026.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Equity Compensation, Director Compensation